Genetically Modified Microbial Cells Metabolizing S-Lignin Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current microbial strains, such as Pseudomonas putida KT2440, have limited capacity to metabolize S-lignin derived compounds like syringate and 3-O-methyl gallate, hindering the conversion of lignin biomass into valuable fuels and chemicals.
Innovation Solution
Genetically modified microbial cells expressing vanillate demethylase (VanAB) and 3,4-dioxygenase (PcaHG) are engineered to metabolize S-lignin decomposition molecules, enabling the production of intermediates like 2-hydroxy-2H-pyran-4,6-dicarboxylic acid (PDC), which can be further converted into useful chemicals and fuels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current microbial strains (Pseudomonas putida KT2440) are used, then the system is simple and easy to operate, but the capacity to metabolize S-lignin derived compounds is limited
Solution Approach 1:
The patent changes the metabolic parameters of the microbial strain by introducing specific enzymatic pathways (vanillate demethylase VanAB and 3,4-dioxygenase PcaHG) that enable the bacteria to metabolize S-lignin derived compounds like syringate and 3-O-methyl gallate. This parameter change transforms the metabolic capability without fundamentally altering the host organism structure
Solution Approach 2:
The patent uses intermediary enzymes (VanAB and PcaHG) as mediators to bridge the gap between the microbial strain's natural metabolic capacity and its ability to process S-lignin compounds. These enzymes act as catalysts that enable the conversion of recalcitrant lignin derivatives into useful intermediates like PDC, overcoming the metabolic limitations of the native strain
2Productivity
If genetically modified microbial cells are engineered to metabolize S-lignin compounds, then the production of valuable intermediates is enhanced, but the manufacturing complexity increases
Solution Approach 1:
The patent segments the complex metabolic pathway into distinct enzymatic steps, with VanAB performing demethylation of syringate and 3-O-methyl gallate, and PcaHG performing 3,4-dioxygenation to produce PDC. This segmentation allows for targeted genetic modification and easier optimization of each step independently
Solution Approach 2:
The patent performs preliminary genetic engineering to establish the VanAB and PcaHG pathways in the microbial strain before exposing it to S-lignin compounds. This preliminary action ensures the strain is pre-equipped with the necessary metabolic machinery, enabling direct conversion of substrates to products without additional processing steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered microbial cells efficiently convert S-lignin derived molecules into PDC and other intermediates, enhancing the production of valuable compounds and demonstrating improved utilization of lignin biomass, with strains like CJ486 achieving up to 3.38 mM PDC production.
Implementation Method 1
the expression of a vanillate demethylase, where the microbial cell is capable of metabolizing at least one S-lignin decomposition molecule including at least one of syringate and/or 3-O-methyl gallate
Implementation Method 2
the expression of a 3,4-dioxygenase. In some embodiments of the present disclosure, the 3,4-dioxygenase may include PcaHG
Implementation Method 3
the genetically modified microbial cell is capable of producing gallate. In some embodiments of the present disclosure, the genetically modified microbial cell may be capable of producing at least one of 2-hydroxy-2H-pyran-4,6-dicarboxylic acid (PDC)
Data Source
AI summary
The present disclosure relates to a genetically modified microbial cell that includes a genetic modification resulting in the expression of a vanillate demethylase, where the microbial cell is capable of metabolizing at least one S-lignin decomposition molecule including at least one of syringate and/or 3-O-methyl gallate, and the genetically modified microbial cell is capable of producing gallate. In some embodiments of the present disclosure, the vanillate demethylase may include VanAB.